We are attending AASLD The Liver Meetingยฎ 2026 in Denver, CO

APASL 2025

Beijing | 26-30 March, 2025

APASL 2025 Accepted abstracts

HistoIndex had 10 accepted abstracts forย  ๐—”๐—ฃ๐—”๐—ฆ๐—Ÿ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฑ ๐—–๐—ผ๐—ป๐—ณ๐—ฒ๐—ฟ๐—ฒ๐—ป๐—ฐ๐—ฒ in Beijing.ย 

We had the privilege of presenting our latest research through 5 poster presentationsย and 5 oral sessions, sparking great discussions with the global hepatology community.

E-Poster Abstracts

EP0858 Clinicopathologic significance of fibrosis patterns in HCC andย ย  cholangiocarcinomaย 

EP0349 Gender-based difference in patterns of Metabolic Dysfunction-Associated Steatotic Liver disease associated hepatocellular carcinoma induced by diethylnitrosamine combined western diet in mice.

EP0377 Different fibrosis parts correlated with different types of vascular proliferation in two independent MASLD cohorts

EP1035ย  Impact of liver biopsy size on fibrosis evaluation using second harmonic generation/two-photon excitation fluorescence microscopyย 

ย 

Oral Presentations

ORAL SESSION 12: Metabolic Dysfunction-Associated Fatty Liver Disease
(MAFLD) and Toxicity

Room 403, Level 4
15:30-16:30 | 28 Mar

ย 

16:10-16:20 OP0077 ASSESSMENT OF FIBROSIS CHANGE RATES IN MASH DRUG-TRIAL PLACEBO-ARM VIA PATHOLOGIST READINGS AND qFIBROSIS VALUESย 

16:20-16:30 OP0078 AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY studyย 

ย 

ORAL SESSION 64: New Techonology

Room 405, Level 4
10:00-11:00 l 30 Mar

ย 

10:00-10:10 OP0383 Stain-free digital pathology imaging reveals microarchitectural insights into disease activity and scar evolution to enable outcome prediction in metabolic dysfunction-associated steatotic liver diseaseย 

ย 

ORAL SESSION 33:Liver Fibrogenesis and Cirrhosis
Room 405, Level 4
11:00-12:00 | 29 Mar

ย 

11:00-11:10 OP0199 EVALUATING IMPACT OF WEIGHT CHANGES ON HISTOLOGICAL PATTERNS OF LIVER FIBROSIS IN MASH: IMPLICATIONS FOR SPATIAL INTERROGATION

ย 

ORAL SESSION 37: Metabolic Dysfunction-Associated Fatty Liver Disease
(MAFLD) and Toxicity


Room 403, Level 4
13:30-14:30 | 29 Mar

ย 

14:00-14:10 OP0226 Dietary change affects steatosis patterns in hepatocellular carcinoma with Metabolic Dysfunction-Associated Steatotic Liver Disease analyzing by SHG/TPE microscopy imaging combined with scRNA-seqย 

ย 

Poster Abstract

PP0545ย  AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis – results of the FASCINATE-2 studyย 

ย ย 

Get the latest updates about our events